Trial Profile
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 08 Aug 2023 Status changed from active, no longer recruiting to completed.
- 02 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 03 Jan 2022 Planned End Date changed from 1 Feb 2022 to 1 Jul 2022.